Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
| CAPS Rating |
|
|---|
LXRX
VS S&P 500 (SPY)
LXRX News and Commentary
- Orphan Drug Status for Lexicon Drug - Analyst Blog – NASDAQ
- 2-Star Stocks Poised to Plunge: Lexicon Pharmaceuticals? – The Motley Fool
- Wall Street's Buy List – The Motley Fool
- Avoid This Biotech Stock – The Motley Fool
- Lexicon Reveals Positive Effects of Potential Pre-Diabetes Drug – Fox Business
- Lexicon Pharmaceuticals' CEO Discusses Q2 2011 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- Investing 101: Rallying Stocks Under $5 Undervalued to Analyst Estimates – The Motley Fool
- The 10 Most-Watched Diagnostic Substances Stocks – The Motley Fool
- Making Cents in Penny Stocks – The Motley Fool
How do you think LXRX will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
244
Outperform
37
Underperform
All-Star Players
49
Outperform
11
Underperform
Wall Street
5
Outperform
1
Underperform
RSS Headlines
Fool UK
